Novartis

Going, going... Trimeris winds down ops

admin — Mon, 12 May 2008 06:59:57 -0400

Faced with a patent fight that has frustrated efforts to find a buyer, Trimeris has begun to hand back out $80 million in cash as it winds down its operations. The Trimeris board has authorized Read more...

Traditional remedies offer opportunities, challenges

admin — Thu, 08 May 2008 06:59:55 -0400

The Financial Times delves into the push to develop new therapeutics from traditional Chinese and Indian remedies. There have been successes, including the anti-malarial artemether, which was Read more...

ALSO NOTED: Novartis buys bigger stake in Alnylam; FDA chastises ZymoGenetics' marketing campaign;and much more...

admin — Thu, 08 May 2008 06:59:50 -0400

> Novartis has scooped up a bigger share of Alnylam stock. The pharma giant now owns 13.3 percent of the company. Read more...

Novartis' China plans grew from science roundtables

admin — Wed, 07 May 2008 06:59:55 -0400

PharmAsia News sat down with Paul Herrling, head of corporate research at Novartis, and En Li, VP and head of research for Novartis Institutes for BioMedical Research Shanghai, to discuss the Read more...

Novartis reports strong meningitis vaccine response

admin — Tue, 06 May 2008 06:59:54 -0400

In a head-to-head trial, researchers for Novartis say that the experimental meningitis vaccine Menveo produced a more potent immune response than the standard therapy in use. And other data has Read more...

Paratek funds Phase III launch with $40M in VC

admin — Wed, 16 Apr 2008 06:59:55 -0400

Paratek Pharmaceuticals has closed the second tranche on its $40 million round of venture funding. The money allows the Boston-based developer to launch a Phase III trial of the experimental Read more...

SPOTLIGHT: Novartis touts new MS data

admin — Wed, 16 Apr 2008 06:59:53 -0400

Researchers at Novartis say that after three years of therapy in an ongoing Phase II study, the oral FTY720 demonstrated positive results for patients with multiple sclerosis. Data demonstrate that Read more...

Aileron, Heritage Pharma each raise $10M in VC

admin — Tue, 15 Apr 2008 06:59:55 -0400

Novartis Venture Funds and Apple Tree Partners have teamed up to lead a $10 million venture round for Cambridge, MA-based Aileron Therapeutics. Aileron says it will use much of the money to expand Read more...

Antisoma starts licensing spree with cancer deal

admin — Mon, 14 Apr 2008 06:59:56 -0400

Bankrolled by a $125 million licensing deal with Novartis, the UK's Antisoma has turned around and used part of its Read more...

Novartis CEO: Deals possible in diagnostics, vaccines

admin — Mon, 14 Apr 2008 06:59:55 -0400

Novartis AG CEO Daniel Vasella (photo) concedes that his company is going through a rough stage, but insists that a Read more...